Cellectar to participate at the oppenheimer rare & orphan disease summit on may 21, 2021

Florham park, n.j., may 14, 2021 (globe newswire) -- cellectar biosciences, inc. (nasdaq: clrb), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the company will participate and be available for 1x1 meetings at the following upcoming conference:

CLRB Ratings Summary

CLRB Quant Ranking